Australië - Engels - Department of Health (Therapeutic Goods Administration)

d3 australia pty ltd - 34831 - adhesive tape, general-purpose, hypoallergenic - hypofix is a general purpose, dressing sheet manufactured from white non-woven material with a hypoallergenic adhesive providing excellent conformability around joints and contoured parts of the body.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

d3 australia pty ltd - 34864 - adhesive bandage - sports and medical related adhesive tapes, bandages and non adhesive products for medical applications, to support muscles and joints in sporting activities, to prevent injury, and assist in rehabilitation.

Australië - Engels - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - vitamin a = retinyl; vitamin d3 = cholecalciferol; alpha-tocopheryl (vitamin e) - parenteral liquid/solution/suspension - vitamin a = retinyl vitamin-a active 150.0 mg/ml; vitamin d3 = cholecalciferol vitamin-d3 active 1.25 mg/ml; alpha-tocopheryl (vitamin e) vitamin-e active 50.0 mg/ml - nutrition & metabolism - cattle | pigs | sheep | beef | boar | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | ew - vitamin a deficiency | vitamin d deficiency | vitamin e deficiency

Australië - Engels - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - dexpanthenol; vitamin a palmitate; vitamin b12 = cyanocobalamin; vitamin b3 = nicotinamide; vitamin b2 phosphate sodium = riboflavin phosphate sodiu; vitamin b1 hydrochloride = thiamine hydrochloride; vitamin b6 hydrochloride = pyridoxine hydrochloride; vitamin d3 = cholecalciferol; dl-alpha-tocopheryl acetate (vitamin e); vitamin m = folic acid = pga - oral solution/suspension - dexpanthenol ungrouped active 3.33 mg/ml; vitamin a palmitate vitamin-a active 1.0 mg/ml; vitamin b12 = cyanocobalamin vitamin-b12 active 6.67 ug/ml; vitamin b3 = nicotinamide vitamin-b3 active 13.33 mg/ml; vitamin b2 phosphate sodium = riboflavin phosphate sodiu vitamin-b2 active 1.67 mg/ml; vitamin b1 hydrochloride = thiamine hydrochloride vitamin-b1 active 3.33 mg/ml; vitamin b6 hydrochloride = pyridoxine hydrochloride vitamin-b6 active 1.67 mg/ml; vitamin d3 = cholecalciferol vitamin-d3 active 0.1 mg/ml; dl-alpha-tocopheryl acetate (vitamin e) vitamin-e active 3.33 mg/ml; vitamin m = folic acid = pga vitamin-m active 0.5 mg/ml - nutrition & metabolism - horse - racehorse - mineral and nutritional additive | acetonaemia | actinobacillosis | amino acid supplement | amino acids | bone fragility | bone growth | calcium supplement | cartilage strength | copper deficiency | egg shell | fatty acid deficiency | fatty liver | glucose | grass tetany | hepatotoxic drugs | hypocalcaemia | hypomagnesaemia | ileitis | iodine deficiencies | lactating | laxative | l-carnitine supplement | liver abscess | liver damage | lysine deficiencies | milk fever | mineral additive | myopathies | myositis syndrome | pangamic acid | phosphorous supplement | rickets | selenium deficiency | shell strength | soft bone disease | vitamin b12 | vitamin d supplement | vitamin e deficiencies | zinc deficiencies

Australië - Engels - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - calcium carbonate, quantity: 1.25 g (equivalent: calcium, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; croscarmellose sodium; povidone; magnesium stearate; hypromellose; macrogol 8000; chlorophyllin-copper complex; titanium dioxide; carnauba wax - for the treatment of: ? osteoporosis in select patients where vitamin d and calcium supplementation is recommended,prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

Australië - Engels - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - everolimus, quantity: 5 mg - tablet, dispersible - excipient ingredients: butylated hydroxytoluene; crospovidone; hypromellose; lactose monohydrate; mannitol; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica - afinitor is indicated for the: ? treatment of postmenopausal women with hormone receptor-positive, her2 negative advanced breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ? treatment of progressive, unresectable or metastatic, well or moderately differentiated neuroendocrine tumours (nets) of pancreatic origin. ? treatment of progressive, unresectable or metastatic, well-differentiated, non-functional neuroendocrine tumours (net) of gastrointestinal or lung origin in adults. ? treatment of advanced renal cell carcinoma after failure of treatment with sorafenib or sunitinib. ? treatment of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection. ? treatment of patients with tuberous sclerosis complex (tsc) who have renal angiomyolipoma not requiring immediate surgery. ? adjunctive treatment of patients aged 2 years and older with tsc and associated refractory seizures.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - everolimus, quantity: 2 mg - tablet, dispersible - excipient ingredients: butylated hydroxytoluene; crospovidone; hypromellose; lactose monohydrate; mannitol; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica - afinitor is indicated for the: ? treatment of postmenopausal women with hormone receptor-positive, her2 negative advanced breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ? treatment of progressive, unresectable or metastatic, well or moderately differentiated neuroendocrine tumours (nets) of pancreatic origin. ? treatment of progressive, unresectable or metastatic, well-differentiated, non-functional neuroendocrine tumours (net) of gastrointestinal or lung origin in adults. ? treatment of advanced renal cell carcinoma after failure of treatment with sorafenib or sunitinib. ? treatment of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection. ? treatment of patients with tuberous sclerosis complex (tsc) who have renal angiomyolipoma not requiring immediate surgery. ? adjunctive treatment of patients aged 2 years and older with tsc and associated refractory seizures.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - everolimus, quantity: 2.5 mg - tablet - excipient ingredients: magnesium stearate; lactose; lactose monohydrate; hypromellose; butylated hydroxytoluene; crospovidone - afinitor is indicated for the treatment of:,? postmenopausal women with hormone receptor-positive, her2 negative advanced breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ? progressive, unresectable or metastatic, well or moderately differentiated neuroendocrine tumours (nets) of pancreatic origin. ? progressive, unresectable or metastatic, well-differentiated, non-functional neuroendocrine tumours (net) of gastrointestinal or lung origin in adults. ? advanced renal cell carcinoma after failure of treatment with sorafenib or sunitinib. ? subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection. ? patients with tuberous sclerosis complex (tsc) who have renal angiomyolipoma not requiring immediate surgery. afinitor is indicated for the: ? treatment of postmenopausal women with hormone receptor-positive, her2 negative advanced breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ? treatment of progressive, unresectable or metastatic, well or moderately differentiated neuroendocrine tumours (nets) of pancreatic origin. ? treatment of progressive, unresectable or metastatic, well-differentiated, non-functional neuroendocrine tumours (net) of gastrointestinal or lung origin in adults. ? treatment of advanced renal cell carcinoma after failure of treatment with sorafenib or sunitinib. ? treatment of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection. ? treatment of patients with tuberous sclerosis complex (tsc) who have renal angiomyolipoma not requiring immediate surgery. ? adjunctive treatment of patients aged 2 years and older with tsc and associated refractory seizures.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sevelamer carbonate, quantity: 800 mg - tablet, film coated - excipient ingredients: hyprolose; crospovidone; silicon dioxide; mannitol; zinc stearate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; purified talc; xanthan gum; polyvinyl alcohol; lecithin - arx-sevelamer is indicated for the management of hyperphosphataemia in adult patients with stage 4 and 5 chronic kidney disease.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

modere australia pty ltd - potassium iodide, quantity: 65.4 microgram (equivalent: iodine, qty 50 microgram); manganese amino acid chelate, quantity: 20 mg (equivalent: manganese, qty 2 mg); zinc amino acid chelate, quantity: 20 mg (equivalent: zinc, qty 4 mg); iron amino acid chelate, quantity: 40 mg (equivalent: iron, qty 4 mg); calcium hydrogen phosphate dihydrate, quantity: 103.6 mg (equivalent: phosphorus, qty 18.65 mg; equivalent: calcium, qty 24.1 mg); copper gluconate, quantity: 714 microgram (equivalent: copper, qty 100 microgram); dibasic potassium phosphate, quantity: 372.02 mg (equivalent: potassium, qty 167 mg; equivalent: phosphorus, qty 66.15 mg); chromium picolinate, quantity: 120 microgram (equivalent: chromium, qty 15 microgram); calcium amino acid chelate, quantity: 214.5 mg (equivalent: calcium, qty 42.9 mg); magnesium amino acid chelate, quantity: 135 mg (equivalent: magnesium, qty 27 mg); colecalciferol, quantity: 0.0083 mg - tablet, film coated - excipient ingredients: carnauba wax; microcrystalline cellulose; silicon dioxide; hypromellose; magnesium stearate; povidone; macrogol 400; croscarmellose sodium; maize starch; acacia; dl-alpha-tocopherol; sucrose; medium chain triglycerides - helps reduce/decrease free radical damage to body cells ; maintain/support energy production ; maintain/support general health and wellbeing ; maintain/support bone health ; maintain/support bone strength ; vitamin d helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life ; maintain/support blood health ; helps maintain/support transport of oxygen in the body ; maintain/support healthy thyroid gland function ; maintain/support healthy immune system function ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; aid/assist/helps metabolism of (state vitamin/mineral/nutrient) ; maintain/support cognitive function/mental function ; maintain/support skin health